TEVA episode 20261009_TEVA_MIDDAY
Public episode JSON embedded as readable text for automated access.
{
"schema_version": "tryding-agent-episode.v1",
"episode_id": "20261009_TEVA_MIDDAY",
"episode_url": "https://trydingday.com/data/agents/v1/episodes/20261009_TEVA_MIDDAY.html",
"public_page_url": "https://trydingday.com/coverage/teva/2026-10-09/midday/",
"published_at": "2026-10-09T18:36:52.971242Z",
"updated_at": "2026-10-23T22:02:58.695052Z",
"lifecycle": {
"tracking_status": "open",
"active_for_tracking": true,
"stage": "tracking"
},
"instrument": {
"type": "equity",
"symbol": "TEVA",
"exchange": "NYSE",
"name": "Teva Pharmaceutical Industries Limited"
},
"technical_reference": {
"status": "ok",
"reference_price": 41.58,
"model_downside_reference": 39.72,
"model_upside_scenario_1": 43.44,
"model_upside_scenario_2": 45.3,
"atr_14": 1.24,
"method": "reference_price_plus_minus_atr14"
},
"public_content": {
"date": "October 9, 2026",
"generated_at": "2026-10-09T18:36:52.971242Z",
"original_published_at": null,
"session_tag": "midday",
"label": "Market coverage",
"try_label": "Try of the Day",
"public_status": "Try of the Day",
"why_today": "Within the three evidence-backed cases supplied for this review, TEVA remains the most defensible conditional 15-session thesis. This comparison does not establish how TEVA ranks against alternatives for which comparable evidence was not supplied.",
"entry_reasoning": "Panel thesis: The reported FDA approval of Weltruza, together with TEVA's positive relative performance and constructive captured tape, supports a testable follow-through thesis over the next 15 trading sessions. The packet does not establish launch access, uptake or revenue contribution. Invalidation boundary: The thesis weakens if an issuer or regulator source does not confirm the reported approval, or if later company disclosures show limited access or uptake while TEVA's relative strength reverses.",
"reference_price": 41.58,
"scanner": {
"price": 41.58,
"reference": 41.58,
"score": null,
"score_version": "legacy research",
"change": 5.99,
"volume": 8891320.0,
"average_volume": 5300579.0,
"volume_ratio": 1.68,
"rsi": 59.19,
"ema_trend": "39.76 > 39.13 > 37.58",
"position_52w": 99.0,
"atr_14": 1.24,
"vwap": 41.34,
"vwap_state": "above",
"vwap_distance_pct": 0.58,
"vwap_reading": {
"price": 41.34,
"state": "above",
"distance_pct": 0.58
},
"range_position": 0.779,
"gap_pct": 0.0,
"relative_strength": {
"excess_pct": 5.47,
"index": "SPY",
"index_chg_pct": 0.52,
"status": "normal"
},
"volume_percentile": {
"median_vol": 4849300,
"percentile": 98.5,
"status": "exceptional",
"today_vol": 8891320
},
"extension": {
"atr": 1.24,
"dist_atr": 1.98,
"ema_ref": 39.13,
"status": "healthy"
},
"atr_move_signal": {
"atr_pct": 2.98,
"status": "strong",
"z": 2.01
},
"sector_breadth": null,
"sentiment": null,
"sentiment_score": null,
"earnings_warning": {
"days_away": null,
"earnings_date": null,
"has_earnings_soon": false,
"status": "clear"
},
"options_snapshot": null,
"extended_hours": {
"ext_pct": null,
"market_state": "REGULAR",
"phase": "regular",
"post_market_pct": null,
"pre_market_pct": null,
"status": "none"
},
"coiled_spring": {
"component_count": 0,
"components": {},
"count": 0,
"detector_version": "coiled-compression-ohlc.v1",
"reason": "coiled_ohlc_detector_runs_on_research_and_known_ticker_rails",
"schema_version": "coiled-features.v2",
"status": "not_evaluated"
},
"short_pct_float": 2.71,
"days_to_cover": 57.43,
"catalyst": "Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript",
"sector": "Healthcare",
"exchange": "NYSE",
"sec_signal": null
},
"levels": {
"reference": 41.58,
"downside": 39.72,
"upside_1": 43.44,
"upside_2": 45.3
},
"review": {
"score": null,
"status": "Try Of The Day",
"summary": "Within the three evidence-backed cases supplied for this review, TEVA remains the most defensible conditional 15-session thesis. This comparison does not establish how TEVA ranks against alternatives for which comparable evidence was not supplied.",
"views": [
{
"name": "Nate Brooks",
"role": "market structure and timing analyst",
"icon": "📈",
"view": "Start with the day, not one ticker. The supplied snapshot has the broad benchmarks higher and volatility lower, but yields and the dollar edged up. AP also described rising U.S. stocks alongside unsettled oil and yields. Constructive, yes; relaxed, no.",
"reasoning": "I support keeping TEVA as Try of the Day within this three-case comparison. The tape and 20-session relative return still beat the alternatives shown; nothing in this correction adds evidence about the wider candidate set."
},
{
"name": "Priya Nandakumar",
"role": "institutional risk and execution manager",
"icon": "🛡️",
"view": "Oil is still being pushed around by Iran-related uncertainty, and the fresh report puts one-year inflation expectations at 4.7%, up from 4.6% a month earlier. That can keep pressure on rates. A green index snapshot does not make the next fifteen sessions friction-free.",
"reasoning": "The narrower comparison matters. It limits how broadly we can state the result, so I accept a larger unresolved share in the confidence balance. It does not erase the evidence that puts TEVA ahead of the two cases actually supplied."
},
{
"name": "Kenji Osei",
"role": "AI Systems & Market Data Integrity Analyst",
"icon": "🧠",
"view": "The breadth proxy was complete for its frozen 300-name universe, but that is still a subset and the end-of-day layer is absent. It supports a limited reading of the session; it cannot certify participation across the whole market.",
"reasoning": "Then the correction is explicit: compare all three supplied cases, preserve TEVA's identity and thesis, and tell readers the comparison is bounded. We cannot truthfully supply the missing rows under the no-addition instruction."
},
{
"name": "Marcus Feld",
"role": "information, fundamentals and catalyst analyst",
"icon": "🦊",
"view": "TEVA has the most specific product mechanism in this group: trusted reporting says the FDA approved Weltruza, a once-monthly schizophrenia injection. The report is not a direct FDA or company notice, and nothing here shows launch uptake. That distinction stays in the thesis.",
"reasoning": "Within those three, TEVA still has the clearest combination of a specific reported product event and relative strength. That is the same decision, not a new selection. The public wording now makes the three-case boundary explicit."
},
{
"name": "Elena Vartanyan",
"role": "independent statistical auditor",
"icon": "🎯",
"view": "TEVA's session-15 return estimate is 0.519, barely above even. The model's more adverse p10 maximum-excursion estimate is -16.82% from entry; that is a possible deep dip before the horizon ends, not a forecast of the final return. The prepared SEC inputs are not point-in-time validated. I see a useful Raw Try, but I do not support Try of the Day without direct confirmation.",
"reasoning": "The model estimates positive returns of 0.544, 0.558 and 0.519 at sessions 3, 8 and 15. At session 15, the modeled adverse excursion has a -16.820437% p10 and -5.579007% p50. That excursion is the deepest drop from entry within the horizon, not the final return; the estimates remain context, and the prepared SEC inputs are not point-in-time validated. I retain my Raw Try dissent."
}
],
"conviction": {
"status_phrase": "recorded",
"basis": "TEVA remains ahead of HUM and DNA on the supplied event-and-tape evidence; the auditor is right that this three-case comparison does not cover a broader set of alternatives, while source confirmation and uptake remain open.",
"risk": "",
"resolution_pct": 55.0,
"counter_case_pct": 25.0,
"unresolved_pct": 20.0
},
"context_roundtable": {
"mode": "coffee",
"status": "complete",
"consulted_voice_ids": [
"elena",
"marcus",
"kenji",
"priya",
"nate"
],
"summary": "The supplied day context mixes growth, wage and price signals with a supportive but time-bounded market snapshot. Intraday breadth looked constructive, though end-of-day breadth was unavailable; survey headlines lacked readings, and geopolitical or technology announcements did not establish market effects.",
"long_read": "The macro cut offers several different measures rather than a single inflation or growth verdict. Atlanta Fed GDPNow placed its Q3 2026 nowcast at 3.6%, while its September Wage Growth Tracker was reported at 3.9%; the headline characterized the tracker as easing, but the cut gives no prior reading or exact change. OECD reported August energy inflation at 13.6% and separately said food inflation eased, without supplying a food figure here. August U.S. consumer credit was reported higher, but without a value. The Federal Reserve released its 2025 Survey of Consumer Finances, and October University of Michigan consumer-sentiment and inflation-expectations items were listed without their readings. The IMF highlighted targeted transfers as more cost-effective than broad subsidies, but the supplied summary contains no effect size or study detail.\n\nMarket observations are tied to their capture times. The shared market snapshot was complete across its seven rows at 2026-10-09 16:54 UTC. It recorded changes of +0.58% for the S&P 500, +0.48% for the Nasdaq 100, and +0.44% for the Russell 2000. The VIX level was 14.86, with a −3.57% change from 15.41. The 10-year Treasury yield level was 5.253%, up 2.20 basis points from 5.231%; DXY was 102.316, up 0.17%. Gold was quoted at $4,215.30 with a +1.40% change, while WTI was $91.15 with a −0.37% change. A separate fresh intraday breadth proxy at 16:36 UTC showed more advancers than decliners across its covered universe; the end-of-day breadth layer was unavailable. These are dated observations, not a full-close account or a candidate score.\n\nThe Reuters item described the preceding U.S. session as lower for the S&P 500 and Nasdaq while crude rose and semiconductors slumped. The later intraday snapshot had the broad benchmarks higher and WTI lower, but different timestamps do not establish what caused either move. The Treasury action targeting remnants of Iran's shadow fleet is a geopolitical development, not evidence of a measured supply disruption. Anthropic's announcement of a cyber program for critical-infrastructure defense adds a technology and security theme, but the cut supplies no adoption, spending, or earnings outcome.",
"transcript": [
{
"speaker_id": "elena",
"text": "The growth figures are useful orientation, but GDPNow is a nowcast: a model estimate of current-quarter growth before the official GDP release. Atlanta Fed's Q3 estimate was 3.6%, so it frames the outlook while remaining revisable. Its September wage tracker was 3.9%; that is a wage-growth reading, not an inflation rate.",
"source_urls": [
"https://x.com/AtlantaFed/status/2108239231348855087",
"https://x.com/AtlantaFed/status/2108244536119918881"
]
},
{
"speaker_id": "marcus",
"text": "That distinction matters for the price headlines too. OECD reported August energy inflation at 13.6%, while its separate food-inflation item said food inflation eased but gave no figure in this cut. Those signals differ by category; they do not establish that overall household prices eased.",
"source_urls": [
"https://x.com/OECD/status/2108286722488361066",
"https://x.com/OECD/status/2108543049479463355"
]
},
{
"speaker_id": "priya",
"text": "The IMF note says targeted transfers are more cost-effective than broad subsidies. That is a policy-design point about directing support; without the underlying estimates here, we cannot attach a dollar amount or infer a measured effect on households.",
"source_urls": [
"https://x.com/IMFNews/status/2108125420768157800"
]
},
{
"speaker_id": "nate",
"text": "At the 16:54 UTC snapshot, the S&P 500 changed +0.58%, the Nasdaq 100 +0.48%, and the Russell 2000 +0.44%. The VIX, an options-based gauge of expected near-term market swings, stood at 14.86; its exact change was −3.57% from 15.41. That reads as a calmer, positive intraday market snapshot, not a full-day close."
},
{
"speaker_id": "kenji",
"text": "Breadth asks whether rising shares extend beyond a few index leaders. The fresh intraday proxy showed advancers outnumbering decliners, which supports broader participation at that capture time. But the end-of-day breadth layer was unavailable, so we cannot say that this reading held through the close."
},
{
"speaker_id": "marcus",
"text": "Reuters summarized the preceding U.S. session as lower for the S&P 500 and Nasdaq while crude rose and semiconductors slumped. In the later snapshot, WTI was $91.15 with a −0.37% change and gold was $4,215.30 with a +1.40% change. The Treasury action targeting Iran's shadow fleet is a separate event; the timing does not prove it moved oil.",
"source_urls": [
"https://x.com/ReutersBiz/status/2108354257128743333",
"https://x.com/USTreasury/status/2108301161686348240"
]
},
{
"speaker_id": "marcus",
"text": "The Federal Reserve released its 2025 Survey of Consumer Finances, and Michigan's October sentiment and inflation-expectations updates were also listed. The supplied cut has no survey readings or changes, so we cannot say confidence rose or expectations moved. It also reports August consumer credit rose without giving the amount.",
"source_urls": [
"https://x.com/federalreserve/status/2108560007457591745",
"https://x.com/LizAnnSonders/status/2108560037492707376",
"https://x.com/LizAnnSonders/status/2108563278196830240",
"https://x.com/KobeissiLetter/status/2108544668745052305"
]
},
{
"speaker_id": "priya",
"text": "Anthropic announced a cyber program for critical-infrastructure defense. That adds an AI security-use case to the day's policy and technology mix, but the announcement does not quantify adoption, spending, or business outcomes. It should stay a context signal rather than an earnings conclusion.",
"source_urls": [
"https://x.com/AnthropicAI/status/2108302539498414208"
]
}
],
"source_urls": [
"https://x.com/AtlantaFed/status/2108239231348855087",
"https://x.com/AtlantaFed/status/2108244536119918881",
"https://x.com/OECD/status/2108286722488361066",
"https://x.com/OECD/status/2108543049479463355",
"https://x.com/IMFNews/status/2108125420768157800",
"https://x.com/ReutersBiz/status/2108354257128743333",
"https://x.com/USTreasury/status/2108301161686348240",
"https://x.com/federalreserve/status/2108560007457591745",
"https://x.com/LizAnnSonders/status/2108560037492707376",
"https://x.com/LizAnnSonders/status/2108563278196830240",
"https://x.com/KobeissiLetter/status/2108544668745052305",
"https://x.com/AnthropicAI/status/2108302539498414208"
]
},
"context_roundtable_sources": [
{
"event_id": "mi_evt_5784370a81632bc1a9f50bbc",
"headline": "GDPNow Q3 2026 nowcast at 3.6%",
"url": "https://x.com/AtlantaFed/status/2108239231348855087",
"publisher": "Atlanta Fed",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-08T17:39:00Z",
"available_at": "2026-10-08T17:39:00+00:00"
},
{
"event_id": "mi_evt_2d0cb38a050de6cf9af8045d",
"headline": "Wage Growth Tracker eased to 3.9% in September",
"url": "https://x.com/AtlantaFed/status/2108244536119918881",
"publisher": "Atlanta Fed",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-08T17:39:00Z",
"available_at": "2026-10-08T17:39:00+00:00"
},
{
"event_id": "mi_evt_92ca2bbaacff891d1557a34b",
"headline": "Targeted transfers are more cost-effective than broad subsidies",
"url": "https://x.com/IMFNews/status/2108125420768157800",
"publisher": "International Monetary Fund",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-08T19:39:00Z",
"available_at": "2026-10-08T19:39:00+00:00"
},
{
"event_id": "mi_evt_84c7a89c2e89bd11c9b49d36",
"headline": "OECD energy inflation reached 13.6% in August",
"url": "https://x.com/OECD/status/2108286722488361066",
"publisher": "OECD",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-08T20:39:00Z",
"available_at": "2026-10-08T20:39:00+00:00"
},
{
"event_id": "mi_evt_1ce86fbda767e3cf23e65c7b",
"headline": "Anthropic launches cyber program for critical infrastructure defense",
"url": "https://x.com/AnthropicAI/status/2108302539498414208",
"publisher": "Anthropic",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-08T21:39:00Z",
"available_at": "2026-10-08T21:39:00+00:00"
},
{
"event_id": "mi_evt_73d2a340d7c2289038c1b116",
"headline": "Treasury targets remnants of Iran shadow fleet",
"url": "https://x.com/USTreasury/status/2108301161686348240",
"publisher": "US Department of the Treasury",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-08T21:39:00Z",
"available_at": "2026-10-08T21:39:00+00:00"
},
{
"event_id": "mi_evt_9eb13a013c0d7375bef2c4d7",
"headline": "S&P 500 and Nasdaq ended lower as crude rose and semiconductors slumped",
"url": "https://x.com/ReutersBiz/status/2108354257128743333",
"publisher": "Reuters",
"source_quality": "trusted_reporting",
"public_safe": true,
"published_at": "2026-10-09T00:25:00Z",
"available_at": "2026-10-09T00:25:00+00:00"
},
{
"event_id": "mi_evt_7c7c8da725cea944c9691e8f",
"headline": "OECD food inflation eases in August",
"url": "https://x.com/OECD/status/2108543049479463355",
"publisher": "OECD",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-09T13:00:12.488000Z",
"available_at": "2026-10-09T13:00:12.488000+00:00"
},
{
"event_id": "mi_evt_75b33446e0c53ce864628b34",
"headline": "US consumer credit rises in August",
"url": "https://x.com/KobeissiLetter/status/2108544668745052305",
"publisher": "The Kobeissi Letter",
"source_quality": "market_context",
"public_safe": true,
"published_at": "2026-10-09T13:06:38.551000Z",
"available_at": "2026-10-09T13:06:38.551000+00:00"
},
{
"event_id": "mi_evt_0f9df192ffec3e60cb08975e",
"headline": "Federal Reserve releases 2025 Survey of Consumer Finances",
"url": "https://x.com/federalreserve/status/2108560007457591745",
"publisher": "Federal Reserve",
"source_quality": "primary",
"public_safe": true,
"published_at": "2026-10-09T14:07:35.585000Z",
"available_at": "2026-10-09T14:07:35.585000+00:00"
},
{
"event_id": "mi_evt_21f3c6ab883de9f5d0e91c0c",
"headline": "University of Michigan October consumer sentiment",
"url": "https://x.com/LizAnnSonders/status/2108560037492707376",
"publisher": "Liz Ann Sonders",
"source_quality": "market_context",
"public_safe": true,
"published_at": "2026-10-09T14:07:42.746000Z",
"available_at": "2026-10-09T14:07:42.746000+00:00"
},
{
"event_id": "mi_evt_4a151a4e7588b66b9ab5d68d",
"headline": "University of Michigan October inflation expectations",
"url": "https://x.com/LizAnnSonders/status/2108563278196830240",
"publisher": "Liz Ann Sonders",
"source_quality": "market_context",
"public_safe": true,
"published_at": "2026-10-09T14:20:35.390000Z",
"available_at": "2026-10-09T14:20:35.390000+00:00"
}
]
},
"updates": [
{
"day": 10,
"timestamp": "2026-10-23T22:02:58.695052Z",
"date": "Session 10 · Oct 23, 2026 · 18:02 NYSE",
"text": "The tracked loss narrowed 0.10 points to 5.22% on session 10, though the latest capture still showed a 1.99% decline to $39.41 below VWAP. TEVA remains 4.47 points behind Healthcare over 20 sessions; the reported Weltruza approval keeps the catalyst testable, but the package still shows no launch access, uptake or commercial contribution.",
"price": 39.41,
"pct": -5.22,
"return_vs_entry_pct": -5.22,
"return_vs_base_pct": -5.22,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.1,
"session_day": 10,
"reference_price": 41.58,
"reference_text": "$39.41 · -5.22% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-23T21:21:49Z",
"vwap_as_of": null
},
{
"day": 10,
"timestamp": "2026-10-23T20:15:24.510922Z",
"date": "Session 10 · Oct 23, 2026 · 16:15 NYSE",
"text": "The tracked loss widened 0.37 points to 5.32% on session 10. Shares fell 2.09% to $39.37 below VWAP on 0.71 times usual volume; the 20-session Healthcare lag is 4.41 points. The market test weakened after Weltruza approval, while this handoff provides no new evidence of launch uptake or commercial contribution.",
"price": 39.37,
"pct": -5.32,
"return_vs_entry_pct": -5.32,
"return_vs_base_pct": -5.32,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.02,
"session_day": 10,
"reference_price": 41.58,
"reference_text": "$39.37 · -5.32% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-23T19:22:12.987963Z",
"vwap_as_of": null
},
{
"day": 10,
"timestamp": "2026-10-23T14:56:34.161537Z",
"date": "Session 10 · Oct 23, 2026 · 10:56 NYSE",
"text": "The tracked loss widened 1.66 points to 4.95% on session 10 as shares fell 1.04% to $39.79, though they stayed 0.84% above the session average on 1.96 times usual time-adjusted activity. The 20-session Healthcare lag narrowed to 3.88 points, but the evidence still does not show Weltruza approval turning into access, uptake or revenue.",
"price": 39.79,
"pct": -4.95,
"return_vs_entry_pct": -4.3,
"return_vs_base_pct": -4.3,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.01,
"session_day": 10,
"reference_price": 41.58,
"reference_text": "$39.79 · -4.30% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-23T14:06:04.621810Z",
"vwap_as_of": null
},
{
"day": 9,
"timestamp": "2026-10-22T22:04:32.563215Z",
"date": "Session 9 · Oct 22, 2026 · 18:04 NYSE",
"text": "The tracked loss narrowed 0.34 points to 3.29% on session 9, despite shares falling 1.01% to $40.21 on 0.71 times average volume. The 20-session return still trails Healthcare by 6.75 points, and the separate duvakitug study update does not establish Weltruza access or uptake; the central commercial question remains open.",
"price": 40.21,
"pct": -3.29,
"return_vs_entry_pct": -3.29,
"return_vs_base_pct": -3.29,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.35,
"session_day": 9,
"reference_price": 41.58,
"reference_text": "$40.21 · -3.29% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-22T20:00:36Z",
"vwap_as_of": null
},
{
"day": 9,
"timestamp": "2026-10-22T19:38:49.428606Z",
"date": "Session 9 · Oct 22, 2026 · 15:38 NYSE",
"text": "TEVA's tracked loss widened 1.32 points to 3.63% on session 9; shares fell 1.37% to $40.07 but held slightly above the session's average price near midrange on 0.54 times usual volume. Its 20-session return now trails Healthcare by 7.20 points, versus 1.88 points in the last note. Teva's separate phase 2b update for investigational duvakitug adds pipeline evidence, but does not confirm Weltruza access or uptake; the active model remains close to even.",
"price": 40.065,
"pct": -3.63,
"return_vs_entry_pct": -3.64,
"return_vs_base_pct": -3.64,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.33,
"session_day": 9,
"reference_price": 41.58,
"reference_text": "$40.06 · -3.64% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": true,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-06560766ff5409c69cc6e0faf40df96e3acec9254701bb49c87ea8d16d00b112",
"price_as_of": "2026-10-22T19:21:50.306215Z",
"vwap_as_of": null
},
{
"day": 8,
"timestamp": "2026-10-21T21:52:31.040445Z",
"date": "Session 8 · Oct 21, 2026 · 17:52 NYSE",
"text": "TEVA widened its tracked loss by 0.55 points to -2.31% on session 8. The latest quote was $40.62, down 0.56%; the available regular-session read sat just below VWAP as activity eased. TEVA now trails Healthcare by 1.88 points over twenty sessions. Without primary confirmation of Weltruza approval, launch access or uptake, the price drift adds little thesis support.",
"price": 40.62,
"pct": -2.31,
"return_vs_entry_pct": -2.31,
"return_vs_base_pct": -2.31,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.55,
"session_day": 8,
"reference_price": 41.58,
"reference_text": "$40.62 · -2.31% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-21T20:32:10Z",
"vwap_as_of": null
},
{
"day": 8,
"timestamp": "2026-10-21T00:36:13.260801Z",
"date": "Session 8 · Oct 20, 2026 · 20:36 NYSE",
"text": "TEVA's tracked loss held at 1.76% on session 8 as shares fell 1.11% to $40.85, 0.28% below VWAP, with 0.43 time-adjusted activity. The stock now trails Healthcare by 0.81 points over 20 sessions; without primary confirmation of Weltruza's reported approval or evidence of launch access and uptake, this drift gives the thesis little new support.",
"price": 40.85,
"pct": -1.76,
"return_vs_entry_pct": -1.76,
"return_vs_base_pct": -1.76,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.7,
"session_day": 8,
"reference_price": 41.58,
"reference_text": "$40.85 · -1.76% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-20T23:20:55Z",
"vwap_as_of": null
},
{
"day": 7,
"timestamp": "2026-10-20T23:09:43.955973Z",
"date": "Session 7 · Oct 20, 2026 · 19:09 NYSE",
"text": "TEVA tracked loss widened 1.11 points to 1.76% as shares fell 0.41% to $41.14, 0.28% below VWAP on 0.47 times average volume. Its 20-session return now trails Healthcare by 2.17 points; the price drift offers little confirmation, while the handoff still lacks primary confirmation of Weltruza approval or evidence of launch access and uptake.",
"price": 41.14,
"pct": -1.76,
"return_vs_entry_pct": -1.06,
"return_vs_base_pct": -1.06,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.41,
"session_day": 7,
"reference_price": 41.58,
"reference_text": "$41.14 · -1.06% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-20T19:32:17.054310Z",
"vwap_as_of": null
},
{
"day": 6,
"timestamp": "2026-10-19T22:19:40.813674Z",
"date": "Session 6 · Oct 19, 2026 · 18:19 NYSE",
"text": "TEVA's tracked loss widened 0.43 percentage points to 0.65% as shares fell 0.46%, ending just 0.01% above VWAP on 0.66 times average volume. Its 20-session return now trails Healthcare by 0.81 points; this price update adds no evidence on the reported Weltruza approval, whose primary confirmation and commercial uptake remain open.",
"price": 41.31,
"pct": -0.65,
"return_vs_entry_pct": -0.65,
"return_vs_base_pct": -0.65,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.4,
"session_day": 6,
"reference_price": 41.58,
"reference_text": "$41.31 · -0.65% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-19T21:28:10Z",
"vwap_as_of": null
},
{
"day": 6,
"timestamp": "2026-10-19T20:01:44.897519Z",
"date": "Session 6 · Oct 19, 2026 · 16:01 NYSE",
"text": "TEVA's tracked loss edged 0.03 points wider to 0.22% as the quote slipped 0.06%, held just 0.01% above VWAP and traded at 0.32 times normal volume. Its 20-session return trails Healthcare by 0.63 points; the reported Weltruza approval still lacks primary confirmation here, and launch access, uptake and revenue contribution remain open questions.",
"price": 41.475,
"pct": -0.22,
"return_vs_entry_pct": -0.25,
"return_vs_base_pct": -0.25,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.06,
"session_day": 6,
"reference_price": 41.58,
"reference_text": "$41.48 · -0.25% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-19T19:21:30.182691Z",
"vwap_as_of": null
},
{
"day": 5,
"timestamp": "2026-10-16T22:05:51.393860Z",
"date": "Session 5 · Oct 16, 2026 · 18:05 NYSE",
"text": "TEVA's tracked loss narrowed 0.27 points to 0.19% as the latest quote rose 0.95%, held 0.24% above VWAP and traded near mid-range on normal volume. Its Healthcare lead is 1.52 points over 20 sessions, but Weltruza's approval still lacks primary confirmation and launch access, uptake and revenue remain unestablished; price support improves without resolving the catalyst.",
"price": 41.5,
"pct": -0.19,
"return_vs_entry_pct": -0.19,
"return_vs_base_pct": -0.19,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.32,
"session_day": 5,
"reference_price": 41.58,
"reference_text": "$41.50 · -0.19% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-16T21:23:15Z",
"vwap_as_of": null
},
{
"day": 5,
"timestamp": "2026-10-16T20:10:58.230312Z",
"date": "Session 5 · Oct 16, 2026 · 16:10 NYSE",
"text": "The tracked loss for TEVA widened 0.45 points to 0.46% despite a 0.63% latest-session rise above the volume-weighted average on 0.76x normal volume. It retains only a 1.32-point 20-session lead over Healthcare; the reported Weltruza approval lacks primary confirmation, while access, uptake and revenue remain unestablished.",
"price": 41.37,
"pct": -0.46,
"return_vs_entry_pct": -0.51,
"return_vs_base_pct": -0.51,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.53,
"session_day": 5,
"reference_price": 41.58,
"reference_text": "$41.37 · -0.51% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-16T19:21:22.647785Z",
"vwap_as_of": null
},
{
"day": 5,
"timestamp": "2026-10-16T14:22:44.863836Z",
"date": "Session 5 · Oct 16, 2026 · 10:22 NYSE",
"text": "TEVA's tracked return improved 1.12 points to a 0.01% loss as the quote rose 1.17% and held 0.14% above VWAP, though volume was only 0.07 of normal. A 1.01-point 20-session lead over Healthcare is modest, and the reported Weltruza approval still lacks primary confirmation; access, uptake and revenue remain unestablished.",
"price": 41.5902,
"pct": -0.01,
"return_vs_entry_pct": 0.02,
"return_vs_base_pct": 0.02,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 1.15,
"session_day": 5,
"reference_price": 41.58,
"reference_text": "$41.59 · +0.02% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-16T14:06:07.820265Z",
"vwap_as_of": null
},
{
"day": 4,
"timestamp": "2026-10-15T22:12:05.949106Z",
"date": "Session 4 · Oct 15, 2026 · 18:12 NYSE",
"text": "TEVA's tracked return fell 0.72 percentage points to a 1.13% loss even as the latest quote rose 0.96% on 1.59 times average volume; post-market trading was 0.34% lower. That makes the tape mixed rather than a confirmed recovery. The Weltruza approval report still lacks primary confirmation in the packet, and launch access, uptake and revenue are not established.",
"price": 41.11,
"pct": -1.13,
"return_vs_entry_pct": -1.13,
"return_vs_base_pct": -1.13,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.58,
"session_day": 4,
"reference_price": 41.58,
"reference_text": "$41.11 · -1.13% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-15T21:01:56Z",
"vwap_as_of": null
},
{
"day": 4,
"timestamp": "2026-10-15T20:17:44.982139Z",
"date": "Session 4 · Oct 15, 2026 · 16:17 NYSE",
"text": "TEVA's tracked return fell 0.70 points to a 0.41% loss even as shares rose 1.55% in the latest capture; price remained just below VWAP and its 20-session lead over Healthcare is effectively flat at 0.10 points. The Weltruza approval thesis has not yet gained market or operating confirmation on launch access, uptake or revenue.",
"price": 41.35,
"pct": -0.41,
"return_vs_entry_pct": -0.55,
"return_vs_base_pct": -0.55,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.92,
"session_day": 4,
"reference_price": 41.58,
"reference_text": "$41.35 · -0.55% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-15T19:21:33.629030Z",
"vwap_as_of": null
},
{
"day": 4,
"timestamp": "2026-10-15T15:34:44.342940Z",
"date": "Session 4 · Oct 15, 2026 · 11:34 NYSE",
"text": "TEVA's tracked return recovered 2.36 points to a 0.29% gain; shares rose 2.49% and held 0.50% above VWAP near the top of the range. The 20-session lead over Healthcare narrowed to 1.00 point, so the price repair is constructive but the Weltruza approval still has no established access, uptake or revenue contribution.",
"price": 41.735,
"pct": 0.29,
"return_vs_entry_pct": 0.37,
"return_vs_base_pct": 0.37,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 2.44,
"session_day": 4,
"reference_price": 41.58,
"reference_text": "$41.73 · +0.37% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-15T14:06:44.673876Z",
"vwap_as_of": null
},
{
"day": 3,
"timestamp": "2026-10-14T21:46:07.581524Z",
"date": "Session 3 · Oct 14, 2026 · 17:46 NYSE",
"text": "TEVA tracked loss widened 0.84 points to 2.07%; shares fell 1.28% in the regular session, ended 1.90% below VWAP near the session low, and were flat after hours. The 20-session lead over Healthcare remains 1.99 points, but the weak close adds pressure to the follow-through case. The reported Weltruza approval still does not establish access, uptake, or revenue contribution.",
"price": 40.72,
"pct": -2.07,
"return_vs_entry_pct": -2.07,
"return_vs_base_pct": -2.07,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.92,
"session_day": 3,
"reference_price": 41.58,
"reference_text": "$40.72 · -2.07% from $41.58 base",
"timing": "",
"market_marker": {
"phase": "post",
"text": "Aftermarket update: $40.72 (0.00% vs regular close) · Oct 14, 2026 · 17:19 NYSE"
},
"extended_hours": {
"phase": "post",
"price": 40.72,
"ext_pct": 0.0,
"as_of": "2026-10-14T21:19:19Z",
"persisted": false
},
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-14T21:19:19Z",
"vwap_as_of": null
},
{
"day": 3,
"timestamp": "2026-10-14T20:37:22.925832Z",
"date": "Session 3 · Oct 14, 2026 · 16:37 NYSE",
"text": "Teva's tracked return fell 1.57 points into a 1.23% loss as shares slipped 0.36% and sat about 1% below VWAP near the day's low. Its 20-session lead over Healthcare remains 3.26 points, but the reversal erases the prior return recovery and still does not confirm the reported Weltruza approval or access and uptake.",
"price": 41.1,
"pct": -1.23,
"return_vs_entry_pct": -1.15,
"return_vs_base_pct": -1.15,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.53,
"session_day": 3,
"reference_price": 41.58,
"reference_text": "$41.10 · -1.15% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-14T19:41:13.876792Z",
"vwap_as_of": null
},
{
"day": 3,
"timestamp": "2026-10-14T15:09:58.242142Z",
"date": "Session 3 · Oct 14, 2026 · 11:09 NYSE",
"text": "TEVA recovered 1.13 points to a tracked gain of 0.34%; shares rose 1.19%, held above VWAP and reached the observed session high. The 20-session lead over Healthcare stands at 5.46 points. The stronger tape does not confirm the reported Weltruza approval, and access or uptake remains unestablished.",
"price": 41.74,
"pct": 0.34,
"return_vs_entry_pct": 0.38,
"return_vs_base_pct": 0.38,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 1.17,
"session_day": 3,
"reference_price": 41.58,
"reference_text": "$41.74 · +0.38% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-14T14:06:37.850462Z",
"vwap_as_of": null
},
{
"day": 2,
"timestamp": "2026-10-13T21:51:19.807333Z",
"date": "Session 2 · Oct 13, 2026 · 17:51 NYSE",
"text": "TEVA's tracked loss narrowed 0.26 percentage points to 0.79% as shares rose 0.19% near VWAP but remained in the lower quarter of the range on dollar turnover 1.16 times average. Its 20-session lead over Healthcare is 3.91 points, while the reported Weltruza approval still lacks issuer or FDA confirmation and access and uptake remain unestablished.",
"price": 41.25,
"pct": -0.79,
"return_vs_entry_pct": -0.79,
"return_vs_base_pct": -0.79,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.32,
"session_day": 2,
"reference_price": 41.58,
"reference_text": "$41.25 · -0.79% from $41.58 base",
"timing": "",
"market_marker": {
"phase": "post",
"text": "Aftermarket update: $41.25 (0.00% vs regular close) · Oct 13, 2026 · 17:28 NYSE"
},
"extended_hours": {
"phase": "post",
"price": 41.25,
"ext_pct": 0.0,
"as_of": "2026-10-13T21:28:12Z",
"persisted": false
},
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-13T21:28:12Z",
"vwap_as_of": null
},
{
"day": 2,
"timestamp": "2026-10-13T20:08:19.837748Z",
"date": "Session 2 · Oct 13, 2026 · 16:08 NYSE",
"text": "Teva’s tracked loss widened 0.26 points to 1.05%; shares slipped 0.12% below VWAP near the lower range on 0.84 times average volume. The 3.55-point 20-session Healthcare lead offers little help with the key gap: Weltruza’s reported approval still lacks issuer or FDA confirmation, and access and uptake are unestablished.",
"price": 41.12,
"pct": -1.05,
"return_vs_entry_pct": -1.11,
"return_vs_base_pct": -1.11,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.67,
"session_day": 2,
"reference_price": 41.58,
"reference_text": "$41.12 · -1.11% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-13T19:24:51.998952Z",
"vwap_as_of": null
},
{
"day": 2,
"timestamp": "2026-10-13T15:29:18.488139Z",
"date": "Session 2 · Oct 13, 2026 · 11:29 NYSE",
"text": "TEVA's tracked loss narrowed 0.20 percentage points to 0.79% as shares rose 0.55% and held 0.23% above the day's volume-weighted average price near the upper range. Its 20-session lead over Healthcare is 4.14 points. The tape is firmer, but the reported Weltruza approval still lacks issuer or FDA confirmation, and the evidence does not establish access, uptake or revenue.",
"price": 41.395,
"pct": -0.79,
"return_vs_entry_pct": -0.44,
"return_vs_base_pct": -0.44,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.55,
"session_day": 2,
"reference_price": 41.58,
"reference_text": "$41.40 · -0.44% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-13T14:06:26.349567Z",
"vwap_as_of": null
},
{
"day": 1,
"timestamp": "2026-10-12T22:08:24.990901Z",
"date": "Session 1 · Oct 12, 2026 · 18:08 NYSE",
"text": "TEVA's tracked loss narrowed 0.93 points to 0.99% as shares edged up 0.17% on 1.32 times average volume, yet closed 0.66% below the volume-weighted average price in the lower part of the range. Its 3.80-point 20-session lead over Healthcare persists, but the packet still lacks issuer or FDA confirmation of the reported approval and evidence of access or uptake; the commercial case remains untested.",
"price": 41.17,
"pct": -0.99,
"return_vs_entry_pct": -0.99,
"return_vs_base_pct": -0.99,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.75,
"session_day": 1,
"reference_price": 41.58,
"reference_text": "$41.17 · -0.99% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-12T21:30:11Z",
"vwap_as_of": null
},
{
"day": 1,
"timestamp": "2026-10-12T20:16:46.034117Z",
"date": "Session 1 · Oct 12, 2026 · 16:16 NYSE",
"text": "TEVA's first tracked session is down 1.78%; the regular-session capture shows shares down 0.60%, 0.48% below VWAP on 0.78 times average volume. The price response does not confirm the reported approval, which remains secondary in this packet; issuer or FDA confirmation, commercial availability and uptake are still unestablished.",
"price": 40.855,
"pct": -1.92,
"return_vs_entry_pct": -1.74,
"return_vs_base_pct": -1.74,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.21,
"session_day": 1,
"reference_price": 41.58,
"reference_text": "$40.85 · -1.74% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-12T18:48:37.209746Z",
"vwap_as_of": null
},
{
"day": 1,
"timestamp": "2026-10-12T19:47:06.820670Z",
"date": "Session 1 · Oct 12, 2026 · 15:47 NYSE",
"text": "TEVA's tracked return is 1.92% below its initial reference on session one; shares are down 0.80% today, 0.66% below their volume-weighted average price and in the lower fifth of the session range on 0.83 times average volume. It still leads Healthcare by 3.03 points over 20 sessions, but the packet does not establish U.S. access, uptake or revenue from the reported Weltruza approval, leaving the commercial path unresolved.",
"price": 40.77,
"pct": -1.92,
"return_vs_entry_pct": -1.95,
"return_vs_base_pct": -1.95,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.95,
"session_day": 1,
"reference_price": 41.58,
"reference_text": "$40.77 · -1.95% from $41.58 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-12T19:23:05.083706Z",
"vwap_as_of": null
}
],
"observed_outcomes": [
{
"label": "+1 sessions",
"status": "complete",
"return": -0.99,
"reference_text": "-0.99% from $41.58 base",
"price": 41.17,
"updated": "Oct 12, 2026 · 17:38 NYSE",
"mfe": -0.22,
"mae": -2.36
},
{
"label": "+5 sessions",
"status": "complete",
"return": -0.19,
"reference_text": "-0.19% from $41.58 base",
"price": 41.5,
"updated": "Oct 16, 2026 · 17:05 NYSE",
"mfe": 0.7,
"mae": -2.36
},
{
"label": "+10 sessions",
"status": "complete",
"return": -5.22,
"reference_text": "-5.22% from $41.58 base",
"price": 39.41,
"updated": "Oct 23, 2026 · 17:05 NYSE",
"mfe": 0.72,
"mae": -5.95
},
{
"label": "+15 sessions",
"status": "pending",
"return": null,
"reference_text": "",
"price": null,
"updated": "",
"mfe": null,
"mae": null
}
],
"candidate_comparison_history": [
{
"day": 1,
"timestamp": "2026-10-12T19:47:06.820670Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-12T19:47:06.820670Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 40.77,
"base_price": 41.58,
"return_since_base_pct": -1.9481,
"session_return_pct": -0.8,
"change_since_prior_pct": -1.1636,
"volume_ratio": 0.83,
"rsi": 58.15,
"vwap": 41.04,
"vwap_distance_pct": -0.6579,
"position_52w_pct": 97.0,
"extended_hours_pct": null,
"as_of": "2026-10-12T19:23:05.083706Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "39.89 > 39.24 > 37.8",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-12T19:23:05.083706Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.2617,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 1.6763,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 1,
"timestamp": "2026-10-12T20:16:46.034117Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-12T20:16:46.034117Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 40.855,
"base_price": 41.58,
"return_since_base_pct": -1.7436,
"session_return_pct": -0.6,
"change_since_prior_pct": 0.2085,
"volume_ratio": 0.78,
"rsi": 58.8,
"vwap": 41.05,
"vwap_distance_pct": -0.475,
"position_52w_pct": 97.2,
"extended_hours_pct": null,
"as_of": "2026-10-12T18:48:37.209746Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "39.9 > 39.25 > 37.8",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": -0.545,
"nasdaq100": 0.1073,
"russell2000": -0.1802
},
"price_as_of": "2026-10-12T18:48:37.209746Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": 0.3167,
"nasdaq100": 0.969,
"russell2000": 0.6815
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": 0.0888,
"nasdaq100": 0.7411,
"russell2000": 0.4536
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7807.24,
"base_price": 7811.54,
"return_since_base_pct": -0.055,
"session_return_pct": -0.055,
"as_of": "2026-10-12T20:14:36.141421Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 30664.697,
"base_price": 30883.148,
"return_since_base_pct": -0.7073,
"session_return_pct": -0.7073,
"as_of": "2026-10-12T20:14:36.141421Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2795.199,
"base_price": 2806.9814,
"return_since_base_pct": -0.4198,
"session_return_pct": -0.4198,
"as_of": "2026-10-12T20:14:36.141421Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 1,
"timestamp": "2026-10-12T22:08:24.990901Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-12T22:08:24.990901Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.17,
"base_price": 41.58,
"return_since_base_pct": -0.9861,
"session_return_pct": 0.17,
"change_since_prior_pct": 0.771,
"volume_ratio": 1.32,
"rsi": 61.13,
"vwap": 41.04,
"vwap_distance_pct": 0.3168,
"position_52w_pct": 98.0,
"extended_hours_pct": 0.0,
"as_of": "2026-10-12T21:30:11Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "39.97 > 39.27 > 37.81",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": 0.225,
"nasdaq100": 0.8773,
"russell2000": 0.6154
},
"price_as_of": "2026-10-12T21:30:11Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": 0.3167,
"nasdaq100": 0.969,
"russell2000": 0.7071
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": 0.0888,
"nasdaq100": 0.7411,
"russell2000": 0.4792
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7807.24,
"base_price": 7811.54,
"return_since_base_pct": -0.055,
"session_return_pct": -0.055,
"as_of": "2026-10-12T22:07:30.030818Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 30664.697,
"base_price": 30883.148,
"return_since_base_pct": -0.7073,
"session_return_pct": -0.7073,
"as_of": "2026-10-12T22:07:30.030818Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2794.48,
"base_price": 2806.9814,
"return_since_base_pct": -0.4454,
"session_return_pct": -0.4454,
"as_of": "2026-10-12T22:07:30.030818Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 2,
"timestamp": "2026-10-13T15:29:18.488139Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-13T15:29:18.488139Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.395,
"base_price": 41.58,
"return_since_base_pct": -0.4449,
"session_return_pct": 0.55,
"change_since_prior_pct": 0.5465,
"volume_ratio": 0.11,
"rsi": 66.74,
"vwap": 41.3,
"vwap_distance_pct": 0.23,
"position_52w_pct": 98.5,
"extended_hours_pct": null,
"as_of": "2026-10-13T14:06:26.349567Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.25 > 39.47 > 37.95",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-13T14:06:26.349567Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 2,
"timestamp": "2026-10-13T20:08:19.837748Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-13T20:08:19.837748Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.12,
"base_price": 41.58,
"return_since_base_pct": -1.1063,
"session_return_pct": -0.12,
"change_since_prior_pct": -0.6643,
"volume_ratio": 0.84,
"rsi": 65.18,
"vwap": 41.22,
"vwap_distance_pct": -0.2426,
"position_52w_pct": 97.9,
"extended_hours_pct": null,
"as_of": "2026-10-13T19:24:51.998952Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.2 > 39.44 > 37.94",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-13T19:24:51.998952Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 2,
"timestamp": "2026-10-13T21:51:19.807333Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-13T21:51:19.807333Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.25,
"base_price": 41.58,
"return_since_base_pct": -0.7937,
"session_return_pct": 0.19,
"change_since_prior_pct": 0.3161,
"volume_ratio": 1.22,
"rsi": 66.05,
"vwap": 41.22,
"vwap_distance_pct": 0.0728,
"position_52w_pct": 98.2,
"extended_hours_pct": 0.0,
"as_of": "2026-10-13T21:28:12Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.22 > 39.45 > 37.95",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": 0.2129,
"nasdaq100": 0.5005,
"russell2000": 1.0312
},
"price_as_of": "2026-10-13T21:28:12Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": 0.2846,
"nasdaq100": 0.5722,
"russell2000": 1.1029
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": 0.0567,
"nasdaq100": 0.3443,
"russell2000": 0.875
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7805.45,
"base_price": 7807.24,
"return_since_base_pct": -0.0229,
"session_return_pct": -0.0229,
"as_of": "2026-10-13T21:50:36.466839Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 30569.48,
"base_price": 30664.697,
"return_since_base_pct": -0.3105,
"session_return_pct": -0.3105,
"as_of": "2026-10-13T21:50:36.466839Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2783.369,
"base_price": 2806.98,
"return_since_base_pct": -0.8412,
"session_return_pct": -0.8412,
"as_of": "2026-10-13T21:50:36.466839Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 3,
"timestamp": "2026-10-14T15:09:58.242142Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-14T15:09:58.242142Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.74,
"base_price": 41.58,
"return_since_base_pct": 0.3848,
"session_return_pct": 1.19,
"change_since_prior_pct": 1.1879,
"volume_ratio": 0.24,
"rsi": 62.14,
"vwap": 41.47,
"vwap_distance_pct": 0.6511,
"position_52w_pct": 99.3,
"extended_hours_pct": null,
"as_of": "2026-10-14T14:06:37.850462Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.53 > 39.66 > 38.1",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": 1.9737,
"nasdaq100": 2.3835,
"russell2000": 2.4808
},
"price_as_of": "2026-10-14T14:06:37.850462Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": 1.0454,
"nasdaq100": 1.4552,
"russell2000": 1.5525
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": 0.8175,
"nasdaq100": 1.2273,
"russell2000": 1.3246
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7744.28,
"base_price": 7805.45,
"return_since_base_pct": -0.7837,
"session_return_pct": -0.7837,
"as_of": "2026-10-14T15:07:18.695896Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 30204.63,
"base_price": 30569.48,
"return_since_base_pct": -1.1935,
"session_return_pct": -1.1935,
"as_of": "2026-10-14T15:07:18.695896Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2747.4421,
"base_price": 2783.369,
"return_since_base_pct": -1.2908,
"session_return_pct": -1.2908,
"as_of": "2026-10-14T15:07:18.695896Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 3,
"timestamp": "2026-10-14T20:37:22.925832Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-14T20:37:22.925832Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.1,
"base_price": 41.58,
"return_since_base_pct": -1.1544,
"session_return_pct": -0.36,
"change_since_prior_pct": -1.5333,
"volume_ratio": 1.31,
"rsi": 57.34,
"vwap": 41.51,
"vwap_distance_pct": -0.9877,
"position_52w_pct": 97.8,
"extended_hours_pct": null,
"as_of": "2026-10-14T19:41:13.876792Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.4 > 39.6 > 38.07",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-14T19:41:13.876792Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 3,
"timestamp": "2026-10-14T21:46:07.581524Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-14T21:46:07.581524Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 40.72,
"base_price": 41.58,
"return_since_base_pct": -2.0683,
"session_return_pct": -1.28,
"change_since_prior_pct": -0.9246,
"volume_ratio": 1.78,
"rsi": 53.97,
"vwap": 41.51,
"vwap_distance_pct": -1.9032,
"position_52w_pct": 96.9,
"extended_hours_pct": 0.0,
"as_of": "2026-10-14T21:19:19Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.32 > 39.57 > 38.05",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": -0.1717,
"nasdaq100": 0.7438,
"russell2000": 0.6543
},
"price_as_of": "2026-10-14T21:19:19Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": 1.37,
"nasdaq100": 2.2855,
"russell2000": 2.196
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": 1.1421,
"nasdaq100": 2.0576,
"russell2000": 1.9681
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7718.94,
"base_price": 7805.45,
"return_since_base_pct": -1.1083,
"session_return_pct": -1.1083,
"as_of": "2026-10-14T21:45:29.622568Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29950.816,
"base_price": 30569.48,
"return_since_base_pct": -2.0238,
"session_return_pct": -2.0238,
"as_of": "2026-10-14T21:45:29.622568Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2729.5312,
"base_price": 2783.369,
"return_since_base_pct": -1.9343,
"session_return_pct": -1.9343,
"as_of": "2026-10-14T21:45:29.622568Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 4,
"timestamp": "2026-10-15T15:34:44.342940Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-15T15:34:44.342940Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.735,
"base_price": 41.58,
"return_since_base_pct": 0.3728,
"session_return_pct": 2.49,
"change_since_prior_pct": 2.4926,
"volume_ratio": 0.12,
"rsi": 70.25,
"vwap": 41.53,
"vwap_distance_pct": 0.4936,
"position_52w_pct": 99.3,
"extended_hours_pct": null,
"as_of": "2026-10-15T14:06:44.673876Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.6 > 39.77 > 38.2",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-15T14:06:44.673876Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 4,
"timestamp": "2026-10-15T20:17:44.982139Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-15T20:17:44.982139Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.35,
"base_price": 41.58,
"return_since_base_pct": -0.5532,
"session_return_pct": 1.55,
"change_since_prior_pct": -0.9225,
"volume_ratio": 1.03,
"rsi": 68.31,
"vwap": 41.39,
"vwap_distance_pct": -0.0966,
"position_52w_pct": 98.4,
"extended_hours_pct": null,
"as_of": "2026-10-15T19:21:33.629030Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.53 > 39.73 > 38.18",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": 1.2246,
"nasdaq100": 1.6008,
"russell2000": 0.1461
},
"price_as_of": "2026-10-15T19:21:33.629030Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": -0.0637,
"nasdaq100": 0.3125,
"russell2000": -1.1422
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": -0.2916,
"nasdaq100": 0.0846,
"russell2000": -1.3701
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7744.06,
"base_price": 7718.94,
"return_since_base_pct": 0.3254,
"session_return_pct": 0.3254,
"as_of": "2026-10-15T20:13:48.969735Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29935.594,
"base_price": 29950.816,
"return_since_base_pct": -0.0508,
"session_return_pct": -0.0508,
"as_of": "2026-10-15T20:13:48.969735Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2767.85,
"base_price": 2729.5312,
"return_since_base_pct": 1.4039,
"session_return_pct": 1.4039,
"as_of": "2026-10-15T20:13:48.969735Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 4,
"timestamp": "2026-10-15T22:12:05.949106Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-15T22:12:05.949106Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 40.97,
"base_price": 41.58,
"return_since_base_pct": -1.4671,
"session_return_pct": 0.96,
"change_since_prior_pct": -0.919,
"volume_ratio": 1.59,
"rsi": 66.96,
"vwap": 41.39,
"vwap_distance_pct": -1.0147,
"position_52w_pct": 97.8,
"extended_hours_pct": -0.34,
"as_of": "2026-10-15T21:01:56Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.48 > 39.71 > 38.17",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": 0.6346,
"nasdaq100": 1.0108,
"russell2000": -0.4226
},
"price_as_of": "2026-10-15T21:01:56Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": -0.0637,
"nasdaq100": 0.3125,
"russell2000": -1.1209
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": -0.2916,
"nasdaq100": 0.0846,
"russell2000": -1.3488
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7744.06,
"base_price": 7718.94,
"return_since_base_pct": 0.3254,
"session_return_pct": 0.3254,
"as_of": "2026-10-15T22:08:16.381088Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29935.594,
"base_price": 29950.816,
"return_since_base_pct": -0.0508,
"session_return_pct": -0.0508,
"as_of": "2026-10-15T22:08:16.381088Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2767.2693,
"base_price": 2729.5312,
"return_since_base_pct": 1.3826,
"session_return_pct": 1.3826,
"as_of": "2026-10-15T22:08:16.381088Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 5,
"timestamp": "2026-10-16T14:22:44.863836Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-16T14:22:44.863836Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.5902,
"base_price": 41.58,
"return_since_base_pct": 0.0245,
"session_return_pct": 1.17,
"change_since_prior_pct": 1.5138,
"volume_ratio": 0.07,
"rsi": 73.24,
"vwap": 41.53,
"vwap_distance_pct": 0.145,
"position_52w_pct": 99.0,
"extended_hours_pct": null,
"as_of": "2026-10-16T14:06:07.820265Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.7 > 39.88 > 38.31",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-16T14:06:07.820265Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 5,
"timestamp": "2026-10-16T20:10:58.230312Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-16T20:10:58.230312Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.37,
"base_price": 41.58,
"return_since_base_pct": -0.5051,
"session_return_pct": 0.63,
"change_since_prior_pct": -0.5295,
"volume_ratio": 0.76,
"rsi": 72.19,
"vwap": 41.27,
"vwap_distance_pct": 0.2423,
"position_52w_pct": 98.5,
"extended_hours_pct": null,
"as_of": "2026-10-16T19:21:22.647785Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.66 > 39.86 > 38.3",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-16T19:21:22.647785Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 5,
"timestamp": "2026-10-16T22:05:51.393860Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-16T22:05:51.393860Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.5,
"base_price": 41.58,
"return_since_base_pct": -0.1924,
"session_return_pct": 0.95,
"change_since_prior_pct": 0.3142,
"volume_ratio": 1.04,
"rsi": 72.82,
"vwap": 41.27,
"vwap_distance_pct": 0.5573,
"position_52w_pct": 98.8,
"extended_hours_pct": 0.0,
"as_of": "2026-10-16T21:23:15Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.68 > 39.87 > 38.31",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-16T21:23:15Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 6,
"timestamp": "2026-10-19T20:01:44.897519Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-19T20:01:44.897519Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.475,
"base_price": 41.58,
"return_since_base_pct": -0.2525,
"session_return_pct": -0.06,
"change_since_prior_pct": -0.0602,
"volume_ratio": 0.32,
"rsi": 67.22,
"vwap": 41.47,
"vwap_distance_pct": 0.0121,
"position_52w_pct": 98.7,
"extended_hours_pct": null,
"as_of": "2026-10-19T19:21:30.182691Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.84 > 40.02 > 38.43",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-19T19:21:30.182691Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 6,
"timestamp": "2026-10-19T22:19:40.813674Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-19T22:19:40.813674Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.31,
"base_price": 41.58,
"return_since_base_pct": -0.6494,
"session_return_pct": -0.46,
"change_since_prior_pct": -0.3978,
"volume_ratio": 0.66,
"rsi": 65.0,
"vwap": 41.47,
"vwap_distance_pct": -0.3858,
"position_52w_pct": 98.3,
"extended_hours_pct": 0.0,
"as_of": "2026-10-19T21:28:10Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.81 > 40.0 > 38.42",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": -0.8685,
"nasdaq100": -1.631,
"russell2000": -0.7146
},
"price_as_of": "2026-10-19T21:28:10Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": -0.1468,
"nasdaq100": -0.9093,
"russell2000": 0.0071
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": -0.3747,
"nasdaq100": -1.1372,
"russell2000": -0.2208
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7690.73,
"base_price": 7659.44,
"return_since_base_pct": 0.4085,
"session_return_pct": 0.4085,
"as_of": "2026-10-19T22:19:22.795748Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29529.344,
"base_price": 29187.549,
"return_since_base_pct": 1.171,
"session_return_pct": 1.171,
"as_of": "2026-10-19T22:19:22.795748Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2728.298,
"base_price": 2721.37,
"return_since_base_pct": 0.2546,
"session_return_pct": 0.2546,
"as_of": "2026-10-19T22:19:22.795748Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 7,
"timestamp": "2026-10-20T23:09:43.955973Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-20T23:09:43.955973Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.14,
"base_price": 41.58,
"return_since_base_pct": -1.0582,
"session_return_pct": -0.41,
"change_since_prior_pct": -0.4115,
"volume_ratio": 0.47,
"rsi": 65.52,
"vwap": 41.25,
"vwap_distance_pct": -0.2667,
"position_52w_pct": 97.9,
"extended_hours_pct": null,
"as_of": "2026-10-20T19:32:17.054310Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.88 > 40.11 > 38.53",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": -0.694,
"nasdaq100": -0.2777,
"russell2000": -2.0638
},
"price_as_of": "2026-10-20T19:32:17.054310Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": -0.0223,
"nasdaq100": 0.394,
"russell2000": -1.3921
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": -0.2502,
"nasdaq100": 0.1661,
"russell2000": -1.62
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7712.57,
"base_price": 7690.73,
"return_since_base_pct": 0.284,
"session_return_pct": 0.284,
"as_of": "2026-10-20T23:03:36.011816Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29490.283,
"base_price": 29529.344,
"return_since_base_pct": -0.1323,
"session_return_pct": -0.1323,
"as_of": "2026-10-20T23:03:36.011816Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2773.4197,
"base_price": 2728.298,
"return_since_base_pct": 1.6538,
"session_return_pct": 1.6538,
"as_of": "2026-10-20T23:03:36.011816Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 8,
"timestamp": "2026-10-21T00:36:13.260801Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-21T00:36:13.260801Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 41.05,
"base_price": 41.58,
"return_since_base_pct": -1.2747,
"session_return_pct": -1.11,
"change_since_prior_pct": -0.2188,
"volume_ratio": 0.74,
"rsi": 61.9,
"vwap": 41.25,
"vwap_distance_pct": -0.4848,
"position_52w_pct": 97.2,
"extended_hours_pct": 0.49,
"as_of": "2026-10-20T23:20:55Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.82 > 40.08 > 38.52",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": -1.394,
"nasdaq100": -0.9777,
"russell2000": -2.7638
},
"price_as_of": "2026-10-20T23:20:55Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": -0.0223,
"nasdaq100": 0.394,
"russell2000": -1.3921
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": -0.2502,
"nasdaq100": 0.1661,
"russell2000": -1.62
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7712.57,
"base_price": 7690.73,
"return_since_base_pct": 0.284,
"session_return_pct": 0.284,
"as_of": "2026-10-21T00:05:54.964695Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29490.283,
"base_price": 29529.344,
"return_since_base_pct": -0.1323,
"session_return_pct": -0.1323,
"as_of": "2026-10-21T00:05:54.964695Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2773.4197,
"base_price": 2728.298,
"return_since_base_pct": 1.6538,
"session_return_pct": 1.6538,
"as_of": "2026-10-21T00:05:54.964695Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 8,
"timestamp": "2026-10-21T21:52:31.040445Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-21T21:52:31.040445Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 40.58,
"base_price": 41.58,
"return_since_base_pct": -2.405,
"session_return_pct": -0.56,
"change_since_prior_pct": -1.1449,
"volume_ratio": 0.81,
"rsi": 62.62,
"vwap": 40.55,
"vwap_distance_pct": 0.074,
"position_52w_pct": 96.7,
"extended_hours_pct": -0.1,
"as_of": "2026-10-21T20:32:10Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.78 > 40.13 > 38.6",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"benchmark_excess_pct": {
"sp500": -1.1121,
"nasdaq100": -1.8261,
"russell2000": -0.909
},
"price_as_of": "2026-10-21T20:32:10Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"benchmark_excess_pct": {
"sp500": -0.2904,
"nasdaq100": -1.0044,
"russell2000": -0.0873
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"benchmark_excess_pct": {
"sp500": -0.5183,
"nasdaq100": -1.2323,
"russell2000": -0.3152
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7755.15,
"base_price": 7712.57,
"return_since_base_pct": 0.5521,
"session_return_pct": 0.5521,
"as_of": "2026-10-21T16:43:22.625302Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29863.658,
"base_price": 29490.283,
"return_since_base_pct": 1.2661,
"session_return_pct": 1.2661,
"as_of": "2026-10-21T16:43:22.625302Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2783.0996,
"base_price": 2773.4197,
"return_since_base_pct": 0.349,
"session_return_pct": 0.349,
"as_of": "2026-10-21T16:43:22.625302Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 3
}
}
},
{
"day": 9,
"timestamp": "2026-10-22T19:38:49.428606Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-22T19:38:49.428606Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 40.065,
"base_price": 41.58,
"return_since_base_pct": -3.6436,
"session_return_pct": -1.37,
"change_since_prior_pct": -1.2691,
"volume_ratio": 0.54,
"rsi": 54.84,
"vwap": 39.97,
"vwap_distance_pct": 0.2377,
"position_52w_pct": 95.3,
"extended_hours_pct": null,
"as_of": "2026-10-22T19:21:50.306215Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.64 > 40.12 > 38.66",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"price_as_of": "2026-10-22T19:21:50.306215Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0
}
}
},
{
"day": 9,
"timestamp": "2026-10-22T22:04:32.563215Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-22T22:04:32.563215Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "narrative:TEVA:a76eee225c67ffdd:initial",
"decision_at": "2026-10-09T18:36:52.971242Z"
},
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 40.21,
"base_price": 41.58,
"return_since_base_pct": -3.2949,
"session_return_pct": -1.01,
"change_since_prior_pct": 0.3619,
"volume_ratio": 0.71,
"rsi": 56.32,
"vwap": 39.97,
"vwap_distance_pct": 0.6005,
"position_52w_pct": 95.7,
"extended_hours_pct": 0.0,
"as_of": "2026-10-22T20:00:36Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.66 > 40.14 > 38.66",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:21:24+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-22T20:00:36Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T15:17:02.082834+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:20:54+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0,
"day0_close_rows": 3,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
},
{
"day": 10,
"timestamp": "2026-10-23T14:56:34.161537Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-23T14:56:34.161537Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "narrative:TEVA:a76eee225c67ffdd:initial",
"decision_at": "2026-10-09T18:36:52.971242Z"
},
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 39.79,
"base_price": 41.58,
"return_since_base_pct": -4.305,
"session_return_pct": -1.04,
"change_since_prior_pct": -1.0445,
"volume_ratio": 0.38,
"rsi": 51.15,
"vwap": 39.46,
"vwap_distance_pct": 0.8363,
"position_52w_pct": 94.7,
"extended_hours_pct": null,
"as_of": "2026-10-23T14:06:04.621810Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.49 > 40.11 > 38.71",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:21:24+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-23T14:06:04.621810Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T15:17:02.082834+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:20:54+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0,
"day0_close_rows": 3,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
},
{
"day": 10,
"timestamp": "2026-10-23T20:15:24.510922Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-23T20:15:24.510922Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "narrative:TEVA:a76eee225c67ffdd:initial",
"decision_at": "2026-10-09T18:36:52.971242Z"
},
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 39.37,
"base_price": 41.58,
"return_since_base_pct": -5.3151,
"session_return_pct": -2.09,
"change_since_prior_pct": -1.0555,
"volume_ratio": 0.71,
"rsi": 47.62,
"vwap": 39.5,
"vwap_distance_pct": -0.3291,
"position_52w_pct": 93.7,
"extended_hours_pct": null,
"as_of": "2026-10-23T19:22:12.987963Z",
"source": "yfinance_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.41 > 40.07 > 38.69",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:21:24+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-23T19:22:12.987963Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T15:17:02.082834+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:20:54+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0,
"day0_close_rows": 3,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
},
{
"day": 10,
"timestamp": "2026-10-23T22:02:58.695052Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-23T22:02:58.695052Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "narrative:TEVA:a76eee225c67ffdd:initial",
"decision_at": "2026-10-09T18:36:52.971242Z"
},
"rows": [
{
"symbol": "TEVA",
"role": "selected",
"price": 39.41,
"base_price": 41.58,
"return_since_base_pct": -5.2189,
"session_return_pct": -1.99,
"change_since_prior_pct": 0.1016,
"volume_ratio": 0.98,
"rsi": 47.93,
"vwap": 39.5,
"vwap_distance_pct": -0.2278,
"position_52w_pct": 93.8,
"extended_hours_pct": 0.0,
"as_of": "2026-10-23T21:21:49Z",
"source": "sealed_extended_quote",
"name": "Teva Pharmaceutical Industries Limited",
"episode_id": "narrative:TEVA:a76eee225c67ffdd",
"ema_trend": "40.41 > 40.07 > 38.69",
"vwap_state": "below",
"selection_as_of": "2026-10-09T17:21:24Z",
"facts": [
"Trusted reporting dated October 9 described FDA approval of Weltruza, a once-monthly injection for adults with schizophrenia. The packet contains no direct FDA or issuer confirmation and no uptake evidence.",
"The captured quote was up 5.99% on 1.68 times average volume. The $41.60 observation was above the $41.34 session VWAP, with an upward intraday trend.",
"Over 20 sessions TEVA returned 12.11%, versus 3.22% for the healthcare proxy, an excess of 8.89 percentage points.",
"The prepared SEC snapshot, as of September 1 for the quarter ended March 31, reported revenue up 2.34% year over year and net income up 72.43% year over year; operating cash flow was -$40 million. The snapshot is context-only and is not point-in-time validated."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:21:24+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-23T21:21:49Z",
"vwap_as_of": null
},
{
"symbol": "HUM",
"role": "alternative",
"price": 433.0,
"base_price": 435.21,
"return_since_base_pct": -0.5078,
"session_return_pct": 0.2617,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.96,
"rsi": 70.24,
"vwap": 440.3,
"vwap_distance_pct": -1.658,
"position_52w_pct": 95.26,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:39:12Z",
"source": "yfinance_quote",
"name": "Humana Inc.",
"episode_id": "narrative:HUM:fb0efe3b7a66306a",
"ema_trend": "400.61 > 394.58 > 392.01",
"vwap_state": "below",
"selection_as_of": "2026-10-09T15:17:02.082834Z",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T15:17:02.082834+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:39:12Z",
"vwap_as_of": null
},
{
"symbol": "DNA",
"role": "alternative",
"price": 13.0044,
"base_price": 13.2535,
"return_since_base_pct": -1.8795,
"session_return_pct": 0.0338,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"vwap": 12.65,
"vwap_distance_pct": 2.8016,
"position_52w_pct": 72.94,
"extended_hours_pct": null,
"as_of": "2026-10-09T20:44:59Z",
"source": "yfinance_quote",
"name": "Ginkgo Bioworks Holdings, Inc.",
"episode_id": "narrative:DNA:110e3ec9f094a86a",
"ema_trend": "12.08 > 10.75 > 9.29",
"vwap_state": "above",
"selection_as_of": "2026-10-09T17:20:54Z",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-09",
"reference_as_of": "2026-10-09T17:20:54+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-09T20:44:59Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 3,
"candidate_prices": 3,
"candidate_technical": 3,
"benchmark_rows": 0,
"day0_close_rows": 3,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
}
],
"candidates": [
{
"symbol": "HUM",
"name": "Humana Inc.",
"exchange": "NYSE",
"tradingview_url": "https://es.tradingview.com/chart/?symbol=NYSE%3AHUM&interval=60",
"score": 4,
"price": 435.21,
"change": 12.42,
"volume": 2476816,
"avg_volume_3m": 1260607,
"volume_ratio": 1.96,
"rsi": 70.24,
"ema_trend": "400.61 > 394.58 > 392.01",
"position_52w_pct": 95.26,
"vwap": 440.3,
"vwap_distance_pct": null,
"vwap_state": "below",
"facts": [
"The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.",
"The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.",
"The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.",
"Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points.",
"The active model's session-15 positive-return estimate was 0.521, with adverse-MAE quantiles of -17.922386% at p10 and -6.897027% at p50. The prepared SEC context is not point-in-time validated."
],
"role": "alternative",
"selected": false,
"reason": "not_selected"
},
{
"symbol": "DNA",
"name": "Ginkgo Bioworks Holdings, Inc.",
"exchange": "NYSE",
"tradingview_url": "https://es.tradingview.com/chart/?symbol=NYSE%3ADNA&interval=60",
"score": null,
"price": 13.2535,
"change": null,
"volume": 2907166.0,
"avg_volume_3m": 1796431.0,
"volume_ratio": 1.62,
"rsi": 67.1,
"ema_trend": "12.08 > 10.75 > 9.29",
"position_52w_pct": 72.94,
"vwap": 12.65,
"vwap_distance_pct": null,
"vwap_state": "above",
"facts": [
"The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.",
"Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.",
"The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.",
"The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range."
],
"role": "alternative",
"selected": false,
"reason": "not_selected"
}
],
"news": [
{
"title": "SEC 8-K filing",
"url": "https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/d155511d8k.htm"
},
{
"title": "SEC 8-K filing",
"url": "https://www.sec.gov/Archives/edgar/data/818686/000119312526390562/d503082d8k.htm"
},
{
"title": "SEC 8-K filing",
"url": "https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/d81245d8k.htm"
},
{
"title": "Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript",
"url": "https://finnhub.io/api/news?id=19ab9ba0ce811c9ffb7e276b9f4b4afb6d73fa0f44d7ef50cbfac316810f264b"
}
],
"transcript_url": null,
"initial_transcript_anchor": "transcript-entry-0c672fb668412abef4004761181dbb082253f878c99a6831cd89a0b4ed4646d3",
"chart_url": null,
"secondary_chart_url": null,
"forecast_chart_url": null,
"methodology_url": "https://trydingday.com/methodology/",
"track_record_url": "https://trydingday.com/track-record/",
"market_timezone": "America/New_York"
}
}